Parvez M Chowdhury Analyst: Pharmaceuticals and Consumer Goods
|
|
- Johnathan Cole
- 6 years ago
- Views:
Transcription
1 Price BDT Volume Millions Parvez M Chowdhury Analyst: Pharmaceuticals and Consumer Goods parvez@bracepl.com Beximco Pharmaceuticals Limited December 27, 2010 Rating: OUTPERFORM Company Summary 52-week Price Range (BDT) Current Price month Fair Price Cash Dividend 1.00 Total Return 19.93% Number of Shares MM Float 89.00% Average daily volume MM BDT BDT 2009A 2010E 2011E Revenue (MM BDT) 4, , ,860.3 Ops Income (MM BDT) 1, , ,383.4 Net Income (MM BDT) , ,740.2 Margins 2009A 2010E 2011E Gross Margin 47.29% 51.00% 51.00% Operating Margin 20.57% 26.70% 26.90% Net Margin 12.83% 18.37% 19.64% Growth 2009A 2010E 2011E Revenue Growth 21.40% 40.00% 30.00% Net Income Growth 14.56% % 39.01% Per Share (BDT) 2009A 2010E 2011E EPS BVPS CFPS Dividend Valuation 2009A 2010E 2011E P/E 45.4x 22.6x 16.3x P/B 2.6x 1.8x 1.6x EV/EBITDA 14.8x 8.0x 6.0x Other 2009A 2010E 2011E Debt/equity 33.85% 25.00% 25.00% Debt/assets 18.53% 18.67% 18.54% ROA 3.60% 6.05% 7.73% ROE 5.86% 9.30% 10.40% 250 Price Performance - Last 12 Months Beximco Pharmaceuticals Limited (BPL) is one of the leading pharmaceutical manufacturing companies in Bangladesh. Considered as a technological leader among the local manufacturers, BPL currently holds the third position in local sales among all pharmaceutical companies in Bangladesh. The company has established an extensive distribution network that supports some of the best-selling products in the local market. With a highly ambitious expansion program, BPL has been able to eliminate some capacity bottlenecks, which have been holding off their growth in the recent past. Moreover, the company has increased its focus on exports in recent times. With its state of the art manufacturing plants and certifications from advanced market regulators, BPL is already in an advanced stage of becoming one of the first truly export-oriented pharmaceutical companies in the country. Although the company has witnessed quite a bit of dilution largely due to conversion of preference shares to common shares and issuing of stock dividends, we believe the growth prospects are high. However, the true potential may not become evident till the end of We initiate our coverage of Beximco Pharma with an OUTPERFORM rating and estimate a 12-month fair price of BDT Our recommendation considers the growth prospect, sound business model, good management, and consistent dividend payout. Our estimated fair price is based on an estimated 2012 EPS of BDT and a P/E multiple of 18.0x as well as 2012 BVPs of BDT and P/B multiple of 2.0x. With 2010 estimated dividend yield of 0.7%, this price indicates a total return of 19.9% by the end of Table 1: Performance Snapshot Source: Company Annual Reports and BRAC EPL Estimates Net Sales (MM BDT) 3, , , , , ,632.4 YoY Growth -2.84% 11.49% 21.40% 40.00% 30.00% 20.00% Operating Income (MM BDT) , , , ,934.5 YoY Growth % 52.54% 0.25% 81.74% 30.97% 23.12% Net Income (MM BDT) , , ,110.3 YoY Growth % 54.46% 14.56% % 39.01% 21.27% EBITDA (MM BDT) 1, , , , , ,162.0 YoY Growth % 53.31% 0.98% 82.51% 31.34% 23.03% EBITDA Margin 37.52% 51.59% 42.92% 55.95% 56.53% 57.95% 0 0 Volume Price
2 Company Profile Beximco Pharmaceuticals Limited (BPL) is a part of Beximco Group, the largest private sector industrial conglomerate in Bangladesh. BPL develops, manufactures and markets both finished dosage form branded generic pharmaceutical products and active pharmaceutical ingredients (APIs), with products including solid dose forms, Metered Dose Inhalers, Nasal Sprays, Large Volume Intravenous Fluids, Suppositories, and Creams/Ointments. BPL produces and markets 'branded generics' for most diseases ranging from AIDS to cancer, from infection to asthma, from hypertension to diabetes, for both national and international markets. The company also manufactures active pharmaceutical ingredients and intravenous fluids and contract manufacture for major international brands of leading multinational companies. BPL utilizes state of the art manufacturing facilities. BPL also has outstanding reverse engineering capabilities. Incorporated in 1976, BPL started off as a distributor of pharmaceutical products. It imported products from global MNCs such as Bayer AG of Germany and Upjohn Inc. of USA and sold them in the local market. It eventually graduated to a manufacturer and distributor of these products in local market under licensing agreements. During the early 80s, BPL launched its own products in the local market. Beximco started its exports operation in the early 90s with APIs. Today BPL is one of the largest exporter of medicines from Bangladesh. BPL employs more than 2,400 staff, including over 300 qualified professionals such as pharmacists, chemists, microbiologists, engineers, doctors etc. BPL is the third largest pharmaceutical manufacturing company in Bangladesh with net sales of BDT 4.87 million, according to the 2009 annual report. Industry and Competition The pharmaceutical sector, which is widely regarded as a hi-tech industry, is the most developed among the manufacturing industries in Bangladesh. Roughly 250 companies are operating in the market. According to IMS, a US-based market research firm, the retail market size is estimated to be around BDT 55 billion, which grew by 16.8% in The market size in 2008 was BDT 47 billion with a growth of 6.9%. The actual size of the market may vary slightly since IMS does not include the rural market in their survey. The retail market is about 90% of the total market. In that respect, the total market size is more than BDT 60 billion. One of the fastest growing sectors, Bangladesh s pharmaceutical industry is the third largest tax paying industry in the country. Bangladeshi pharmaceutical firms focus primarily on branded generic final formulations using imported APIs. Branded generics are a category of drugs including prescription products that are either novel dosage forms of off-patent products produced by a manufacturer that is not the originator of the molecule, or a molecule copy of an off-patent product with a trade name. About 80% of the drugs sold in Bangladesh are generics and 20% are patented drugs. The country manufactures about 450 generic drugs for 5,300 registered brands which have 8,300 different forms of dosages and strengths. These include a wide range of products from anti-ulcerants, flouroquinolones, anti-rheumatic non-steroid drugs, non-narcotic analgesics, antihistamines, and oral anti-diabetic drugs. Some larger firms are also starting to produce anti-cancer and anti-retroviral drugs. Domestically, Bangladeshi companies including the locally based MNCs produce 95%-97% of the drugs and the rest are imported. Although about 250 pharmaceutical companies are registered in Bangladesh, less than 100 are actively producing drugs. The domestic market is highly concentrated and competitive. However, the local manufacturers dominate the industry as they enjoy approximately 87% of market share, while multinationals hold a 13% share. Another notable feature of this sector is the concentration of sales among a very small number of top companies. The top 10 players control around two-third of the market share while the top 15 companies cover 77% of the market. Figure 1: Market share concentration MNCs 13% Others 20% Top Ten 67% Source: BAPI and newspaper reports Page 2
3 Square Pharmaceuticals is the stand out market leader with a market share of 19.3% which posted domestic revenue of BDT 11.2 billion in the last four quarters (Apr 09 - Mar 10). Square s nearest competitors are Incepta Pharmaceuticals and Beximco Pharmaceuticals with market shares of 8.5% and 7.6% respectively. Incepta and Beximco had BDT 4.9 billion and BDT 4.4 billion in domestic sales for the last four quarters. Although a number of MNCs are operational in Bangladesh market, no MNCs are in the top ten in terms of domestic sales. Table 2: Domestic market share of companies Revenue April 09 - March 10 (MM BDT) Revenue Market 2009 Share (MM BDT) Market Share Top Companies Square Pharmaceuticals 11, % 10, % Incepta Pharmaceuticals 4, % 4, % Beximco Pharmaceuticals 4, % 4, % Opsonin Pharmaceuticals 2, % 2, % Eskayef Pharmaceuticals 2, % 2, % Acme Laboratories 2, % 2, % Renata Limited 2, % 2, % ACI Limited 2, % 2, % Aristopharma 2, % 2, % Drug International 2, % 2, % Sanofi-Aventis 1, % 1, % GlaxoSmithKline 1, % 1, % Novo Nordisk 1, % % Sandoz % % Novartis % % Others 13, % 13, % Total 57, % 54, % Source: BAPI and newspaper reports Figure 2: Growth rate of companies in Apr 09 Mar 10 Top Ten Company Growth Apr 09 - Mar 10 ACI Limited 7.9% Acme Laboratories 8.0% Aristopharma 13.6% Square Pharmaceuticals 13.9% Sector 18.4% Beximco Pharmaceuticals 22.0% Eskayef Pharmaceuticals 27.3% Renata Limited 28.5% Incepta Pharmaceuticals 31.0% Opsonin Pharmaceuticals 31.7% Drug International Source: Newspaper reports 39.2% The most important therapeutic group in the Bangladeshi market are Systemic Antibiotics. They account for almost 30% of the market. The second therapeutic group, Anti-acids, are much less relevant in terms of market, as well as from a public health perspective. Vitamins, Analgesics, Mineral supplements, Cough and Cold preparations and muscle relaxants also figure prominently. It is to be noted, that typical developed market therapeutic groups like those addressing diabetes, cardiovascular diseases, allergies or psychological disorders also are among the most important in Bangladesh, whereas HIV/AIDS and Antimalarial drugs are not. Because Bangladesh API capacity is insignificant, pharmaceutical companies import approximately 80% of their APIs. Coupled with the necessity to import machines, it is one of the main disadvantages in terms of cost when compared to India. The leading manufacturers are therefore going into API manufacturing, focusing mainly on Antibiotics, but also other drugs, such as anti-cancer drugs. For many APIs, the domestic market is too small to justify an API manufacturing plant. This stresses the fact that whereas several Bangladeshi manufacturers have the know-how to manufacture APIs, the initial investment and the production scale required are high. This means that in order to establish API manufacturing e.g. for Antiretroviral APIs in Bangladesh, the manufacturers would need to be sure of their access to several export markets. Product Portfolio of Beximco Pharma Beximco has a wide range of product portfolio with more than 225 generic brands in over 400 strengths and dosage forms. Many of its brands have strong command over their respective therapeutic categories. Neoceptin-R is the number one brand in terms of revenue volume while Napa is the number one brand in terms of units sold among all pharmaceutical products in Bangladesh local market. One of BPL s major strengths lies with its sales and marketing team. It has one of the largest distribution channels in the pharmaceutical industry. The sales force of Beximco, led by a large number of medical representatives, is one of the most aggressive among all local manufacturers. This ensures that BPL s products always have a considerably large outreach. Page 3
4 Product Offerings by Dosage Forms BPL develops, manufactures and markets both finished dosage form branded generic pharmaceutical products (about 400 products in the range) and active pharmaceutical ingredients (APIs), with products including solid dose forms, Metered Dose Inhalers, Nasal Sprays, Large Volume Intravenous Fluids, Suppositories, and creams/ointments. Metered Dose Inhalers (MDIs) Beximco Pharma is one of the few companies who has the technology and expertise to manufacture CFC-free HFA MDIs. International market development activities in South East Asian, Middle Eastern and Latin American countries over the last 2 years have resulted in establishment of distributor and contract manufacturing agreement in approximately 20 countries. Product registration activities have commenced in most of these countries. Partnership interests and requests are received to do collaborative respiratory MDI market development from world's leading players, especially from Europe and USA. One MOU is already signed with a company based in USA and few are in the pipeline. Since CFC based products are not going to be produced after December 2009 (especially in all developed markets), it is expected that there will be huge shortages of CFC-free inhalers throughout the world including highly regulated markets like US, UK and EU. Beximco is already in an advantageous position here. Solid and semi solid Dosage Forms Beximco Pharma has gained wide acceptance from the physicians at home and abroad for the product quality of its solid dosage form products such as tablets, capsules, suppositories, ointment, cream etc. The company is also one of the largest manufacturer of liquid formulation products such as syrup and suspension etc. in Bangladesh. After getting enlisted with WHO and UNICEF as their global supplier and also due to the certification of Track-II (tablets, capsules, inhaler and sprays) from various regulatory authorities worldwide, the demand for oral solid dosage forms and inhalers is increasing day by day in the international markets. Large Volume Intravenous Fluids Beximco Pharma s large volume IV fluids products currently represent around 40% of the domestic market. Currently, Beximco Pharma is offering only IV fluids in salt and electrolyte market. However, it has no product offerings in Total Parenterals Nutrition (TPN) market. Annual and YTD Quarterly Results Table 3: Profits and Margins (Figures in million BDT) % chg 9M10 9M09 % chg 3Q10 3Q09 % chg 3Q10 2Q10 % chg 4Q09 3Q09 % chg Net Sales 4,868 4,010 21% 4,781 3,472 38% 1,812 1,158 56% 1,812 1,642 10% 1,396 1,158 21% Gross Profit 2,302 2,007 15% 2,416 1,639 47% % % % Operating Profit 1, % 1, % % % % Profit After Tax % % % % % Gross Margin 47% 50% 51% 47% 51% 48% 51% 52% 47% 48% Operating Margin 21% 25% 27% 21% 29% 27% 29% 27% 19% 27% Net Margin 13% 14% 18% 14% 17% 15% 17% 19% 10% 15% Source: Company Quarterly Financial Statements In 2009, Beximco Pharma reached net sales of BDT 4.87 billion posting a healthy growth of 21% and outperforming the industry. The bottom line growth was 15% with a net profit of BDT 625 million. However, operating profit remained almost the same as previous years. This is mostly due to the company s extra efforts to recover some of its market shares from rivals. The company hit a bottleneck in capacity during the past couple of years. The rival companies took advantage of this. Since the pharmaceutical industry in Bangladesh is fiercely competed by the top companies, recovering lost market shares is not an easy task. However, BPL has apparently overcome those problems in 2010 and this is expected to continue in the foreseeable future. Page 4
5 Beximco boosted their efforts through their strong sales force. This has increased their expenses faster than their top line growth resulting in reduced margins in However, the situation seems to have improved considerably as the margins have been increasing steadily in the last couple of quarters. The gross margin, operating margin and net margin for the year 2009 were 47%, 21% and 13% respectively. For the first nine months of 2010 these margins are 51%, 27% and 18% respectively. The quarterly margins also demonstrate an increasing trend. We believe that the margins will stabilize and then continue at that rate for the foreseeable future. Sales Table 4: Local Sales and Exports BDT Local Sales 3,238,165,045 3,587,218,117 3,474,272,775 3,839,563,510 4,596,129,162 Exports 88,857, ,099, ,852, ,603, ,175,753 Total 3,327,022,574 3,702,317,159 3,597,124,812 4,010,167,059 4,868,304,915 Local Sales Growth 39% 11% -3% 11% 20% Exports Growth 12% 30% 7% 39% 60% Total Sales Growth 38% 11% -3% 11% 21% Source: Company Annual Reports Beximco Pharma has been a regular feature in the top three in terms of domestic sales among the pharmaceutical companies in Bangladesh. However, during the period of , the company faced a bit of capacity constraints. The fiercely competitive industry forced the company to relinquish a small portion of market share to its closest rivals. The recent capacity expansion should help it continue with its impressive top line growth and the early signs are positive. As of 2009, the company had local sales and exports contributing 94% and 6% respectively. The management wants to achieve a net sales of BDT 8.4 billion by 2011 and double its current revenue by While it could be challenging, it certainly is achievable. The management also has a target to have an equal contribution from local sales an exports by This seems to be an ambitious target. However, the exports have seen some very robust growth. Therefore, we are likely to see them reach their target in a few years, if not within their targeted timeframe. Margins and profitability Table 6: Margins and Profitability Beximco has been able to maintain a decent Sales 3,327 3,702 3,597 4,010 4,868 margin throughout the last few years despite Gross Profit 1,559 1,731 1,630 2,007 2,302 fluctuations during some tough times between Gross Margin 46.8% 46.8% 45.3% 50.1% 47.3% With capacity constraints out of the Operating Profit way, their margin could stabilize very quickly Operating Margin % % % % 1, % and continue for the foreseeable future. EBITDA 1,497 1,545 1,350 2,069 2,089 Increased focus in the exports market could even EBITDA Margin 45.0% 41.7% 37.5% 51.6% 42.9% Net Profit lead to improvement in margins in the long run. Net Margin 14.7% 12.7% 9.8% 13.6% 12.8% BPL s Current Operational Capability Source: Company Annual Reports Facilities Table 5: Production Capacity and Utilization Tablet & Capsules (Mn pcs) Capacity 1,336 1,566 1,742 1,742 1,742 Actual Production 1,789 2,124 1,774 2,371 2,203 Utilization 134% 136% 102% 136% 126% Bottle, Tube & Cans (Mn pcs) Capacity Actual Production Utilization 112% 105% 92% 87% 115% Bottle-IV (Mn pcs) Capacity Actual Production Utilization 107% 71% 71% 43% 57% Source: Company Annual Reports BPL s operational capability consistently delivers high quality products. Beximco Pharma has a number of self-contained units, namely: Page 5
6 Track I Original plant for tablets, capsules, liquids, cream, ointments, suppositories drops and nasal sprays. Track II New USFDA/ UKMHRA standard Oral Solid Dosage Plant (Currently 2 lines out of total 5 lines are operational) Metered Dose Inhaler (MDI) Plant - Manufactures both CFC & HFA MDIs Intravenous Fluid Plant Injectable, Ophthalmics and Nebulizer Solution Plant Penicillin Formulation Plant Penicillin API Plant Paracetamol API Plant Outsourced products Cephalosporins Outsourcing from 2 manufacturing companies (e.g. Sanofi Aventis) under contract/toll manufacturing arrangement Current Facility Status - Approvals Received GMP Clearance from Therapeutic Goods Administration (TGA) Australia (OSD & MDI) Received GMP Certification from Gulf Co-operative Council (GCC) (OSD & MDI) Received GMP Certification from ANVISA, Brazil (MDI) Qualified by UNICEF (MDI & OSD) Qualified by Global GlaxoSmithKline (MDI) Qualified by Global F Hoff Mann La Roche (OSD) WHO Prequalification for ARVs on going The recent capacity expansion program In order to overcome the capacity bottlenecks and expand its product portfolio, Beximco Pharma has recently undertaken a huge expansion program. The expansion was financed through issuance of fully convertible preference shares worth BDT 4.1 billion. The expansion/diversification projects the company undertook include the following: Completion of additional 3 OSD lines of the USFDA plant Setting up a new MDI Unit with 20 Million Capacity Setting up a new Dry Powder Inhaler plant Nasal Spray facility Setting up a Multi-purpose API Unit (e.g. for Ranitidine, Ciprofloxacin and Omeprazole etc.) Capacity expansion of Paracetamol API plant Capacity expansion of Large Volume Parenterals production facility Capacity expansion of existing Ophthalmic and Injectable facility Setting up Liquid, Cream, Ointment and Sterile manufacturing facility Setting up a new Cephalosporin (finished formulation) manufacturing facility for Oral and Parenteral dosage forms Installation of a new 55,000 sq. feet warehouse Page 6
7 The management aims to achieve equal revenue from exports and domestic market by the year The expansion program is a part of that ambition. Since its current export revenue is not significant, BPL will need to attain exponential growth in exports. This could be quite challenging to achieve. However, the management is trying very hard and the company seem to be going at the right direction. Opportunities in International Markets Beximco Pharma was one of the pioneers in exporting pharmaceuticals from Bangladesh. Today, it is among the largest exporters of pharmaceutical products from Bangladesh. The export market remains a huge opportunity for BPL as it has only scratched the surface thus far owing to capacity constraints resulting in its inability to meet export orders. The management wants to become a world-class manufacturer of pharmaceutical products operating in domestic and international markets, including Least Developed Countries (LDCs, owing to TRIPS Agreement), developing and developed countries. Currently, product registration in several countries is in the pipeline. In line with the goal to enter high margin markets and developed markets, few regulatory audits have already been taken place. Very recently, the Company has received GMP Clearance from Therapeutic Goods Administration (TGA), Australia, GCC and ANVISA, Brazil and expects to commence product exports to these countries from Regulatory audits by UKMHRA, EMEA and USFDA are also expected to take place during 2010 and The company expects that higher margin will be achieved in all these international markets. Along with developed markets, additional 25 countries are also targeted (distributor agreement signed and product registration under process) to enter by These markets/continents include Latin and Central America, South Africa, Africa, Caribbean Island, Pacific Island countries, South Asia and South East Asian countries. Along with own brand marketing, contract manufacturing opportunities are also expected from the developed countries. For example, after receiving TGA s GMP Clearance, the company has already started receiving strong queries for contract manufacturing from Australia and other developed European markets (including Austria, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, UK etc.) where TGA s GMP certification is accepted as a quality standard (under Mutual Recognition Arrangement). Also as mentioned earlier regarding opportunities for inhalers, since only a few companies in the world are operating with their CFC free MDI formulations; there will be huge opportunities for contract manufacturing for reputed MNCs in the coming years. Moreover, opportunities for operating in developed markets with proprietary formulations are also opening up. Contract Manufacturing Opportunity Cost of medication is becoming a major concern even in the developed countries. This particular issue coupled with severe price competition from the generic manufacturers has prompted a number of giant multinational companies to shift or outsource their production from developed to developing and less developed countries, because of huge cost advantage. It is believed that the world pharmaceutical market will continue to see more consolidation than ever across the entire value chain of the pharmaceutical business. Big companies will continue to look for suitable partners in their supply chain management in order to reduce their cost of production. In 2009, the market for contract manufacturing of prescription drugs alone is estimated to be US$ 44 billion. The company has already established partnership with a number of leading global pharmaceutical companies. These partnerships have given the company expertise and know-how to contract manufacture products for reputed MNCs for the developed markets like Europe, USA, and Australia etc. which will commence soon. The Company targets to achieve BDT 120 million sales per month (BDT 1.44 billion annually) from international markets, from the beginning of Page 7
8 Adopting Technology Beximco Pharmaceuticals Limited Beximco Pharma has always been a pioneer in adopting innovative technologies that introduced both sophistication and scale in the business processes. The company s focus on technology is intended to take the company to a standard which would match with other top global generic pharma companies. BPL is the pioneer company from Bangladesh in introducing technology driven (specialty) products in local and international markets. Such specialty products include: - Inhalation aerosols, including Ozone-benign HFA MDIs - Suppositories - Nasal sprays Beximco Pharma has shown its capability in the past by installing state-of-the-art MDI plant and IV fluid plant in collaboration with Pamasol, Switzerland and Pharmaplan, Germany, a sister concern of Fresenius AG, Germany. Experience in Foreign Markets Beximco Pharma is one of the largest exporters of pharmaceuticals from Bangladesh. It is a pioneer in exporting APIs, IV Fluids and hi-tech specialized products. BPL is the first pharmaceutical company in Bangladesh to enter CIS countries. The company is also a pioneer to enter African markets. Beximco Pharma is the only pharmaceutical company in Bangladesh operating in Singapore - one of the most stringently regulated markets in South East Asia. BPL is the only company from Bangladesh supplying medicines to Raffles Hospital and KK Women & Children Hospital of Singapore. Very recently Beximco Pharma has received GMP Clearance from Therapeutic Goods Administration (TGA) Australia for oral solid dosage (tablets & capsules) and inhaler & spray products (for new USFDA standard OSD plant and MDI plant). Under Mutual Recognition Agreements (MRA), TGA s Certificates of GMP Compliance is recognized by over 20 developed countries including Austria, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, UK etc. Pioneer in Exporting APIs from Bangladesh Beximco Pharma s pioneering move to diversify business into manufacture of APIs in 1990 set a new milestone for the pharmaceutical industry of Bangladesh. A number of APIs with good sales potentials are also in the development pipeline of the company. Business Partnerships Beximco Pharma has successful business partnerships with MNCs in contract manufacturing which could lead to further exploration of revenue sharing custom manufacturing arrangements for developed and strategically important international markets such as Latin America, Africa and Middle East and South East Asia. Beximco Pharma has well established partnerships with some of world's leading pharmaceutical companies. BPL started its journey partnering with Bayer AG of Germany and Upjohn Inc. of USA. The company has also partnered with Roche of Switzerland and Pharma Italia Carlo Erba of Italy. Currently, the company contract manufactures world s number one reliever inhaler brand Ventolin for GlaxoSmithKline, and will soon commence to contract manufacture liquid, cream, ointment and suppository products for Novartis. On the other hand, the company has outsourced two of its cephalosporin injectable products from Sanofi Aventis. Collaboration with WHO, UNICEF and ADF BPL is a partner of UNICEF, WHO and Asthma Drug Facility (ADF) in their Millennium Development Goal Commitment for serving and improving human life. Being an enlisted supplier of WHO and UNICEF, BPL has been providing its products to these pioneer organizations since 1998, a way to serve humanity. Very recently, BPL has entered into a Long Term Arrangement (LTA) with Global Supply Division (Copenhagen, Denmark) of United Nations Children s Fund (UNICEF) and ADF, France, to supply CFC free metered dose inhaler products. Page 8
9 Research & Development Beximco Pharmaceuticals Limited Beximco has a strong reverse engineering. It has made a collaborative research agreement with Ciba Specialty Chemicals of Switzerland in proprietary research. In formulation R&D, it focuses principally on developing new formulations, predominantly through reverse engineering. BPL also focuses on simplifying manufacturing processes and improving cost efficiency. Its growing innovation is evident from successful launching of a number of cutting-edge products (for example, Oseltamivir capsules for bird & swine flu treatments, ARVs, anti-cancer products etc.) advanced formulations like multi-layer tablets, sustained release formulations, dispersible tablets, chewable vitamins etc. With considerable experience in MDI formulations, BPL s R&D team has successfully developed a range of CFC-free HFA MDIs. In addition, BPL is also developing a number of APIs to ensure availability of raw materials across the range of therapeutic classes. Beximco Pharma has also signed agreements for collaborative research with leading international API manufacturers to strengthen its API pipeline in order to fully capitalize the WTO patent opportunity. Outlook for the future We believe that with the major bottlenecks in production out of the way, BPL may experience significant improvement in their performance. The margins are expected to improve considerably, as was evident in its 3Q10 results. The gross margin, which was at 47.3% in 2009 has already improved to 50.5% for the first nine months of We estimated it will improve slightly over the course of the next few years and stabilize at 52.0% by Operating margin was at 20.6% in 2009, which Table 7: Margins has moved up to 27.3% for the first three 2009A 2010E 2011E 2012E 2013E 2014E 2015E quarters of We expect the operating margin to continue to improve and stabilize at Gross profit margin 47.3% 51.0% 51.0% 51.5% 51.5% 52.0% 52.0% 28.5% by Net margin in 2009 was at Operating margin 12.8%, which has improved to 17.5% for the Net margin 20.6% 12.8% 26.7% 18.4% 26.9% 19.6% 27.6% 19.8% 27.8% 19.8% 28.4% 20.0% 28.5% 19.9% first nine months of It is expected to go up EBITDA margin 42.9% 55.9% 56.5% 58.0% 58.3% 59.6% 59.8% to 20% by In that connection, the EBITDA Source: Company Annual Report and BRAC EPL Estimates margin is also expected to improve significantly. In 2009, EBITDA margin was at 42.9%. We expect this to improve to almost 60% by In Bangladesh, the pharmaceutical companies have no power on setting prices for the essential drugs, a list of lifesaving drugs decided by the government. Only the government has the power to decide price of these drugs and the revision of price is few and far between. Therefore, the pharmaceutical companies make only marginal profits from these drugs. However, the pharmaceutical companies are free to set prices on products outside of this list. So, the companies make the bulk of their profit from these non-essential drugs. Even then, the companies cannot set prices too high as the purchasing power of the population is limited. This is a limitation of the domestic market of Bangladesh. We expect one of the reasons behind the improvement of margins down the line besides the apparent removal of bottlenecks is that BPL is increasingly focusing its attention to the international market. The same drugs that BPL sell for Tk. 10, for example, could be sold multiple times in Australia, UK or even USA because of the enhanced purchasing power of the consumers of those markets. As a result we think there sales volume will grow significantly over the years. On the flip side, because of the strict quality control and regulations of the developed market Table 8: Local Sales vs. Exports Local Sales (MM BDT) 2, , , , , ,596.1 Exports (MM BDT) Total (MM BDT) 2, , , , , ,868.3 Local Sales % of Total 96.69% 97.33% 96.89% 96.58% 95.75% 94.41% Exports % of Total 3.31% 2.67% 3.11% 3.42% 4.25% 5.59% Local Sales Growth 39.38% 10.78% -3.15% 10.51% 19.70% Exports Growth 11.79% 29.53% 6.74% 38.87% 59.54% Total Sales Growth 38.47% 11.28% -2.84% 11.48% 21.40% Source: Company Annual Reports such as Europe and USA, BPL will need to continuously maintain and renovate their manufacturing plants. This means they are expected to have a large outflow in capital expenditure each year. Since most of the state of the art plants are already in place and waiting for certification, the expenditure should not go up much but rather stay at a stabilized rate. Page 9
10 Valuation The DCF valuation for Beximco Pharmaceuticals gave us a fairly attractive value for the company. We believe even though the real value addition will come after 2012 when the full potential of the ambitious expansion program is realized, the company is slightly undervalued. With a discount rate of 13.0% and terminal growth rate of 6.5%, our DCF valuation provides a fair value of BDT 162 per share, which would be 19.5x of expected 2011 EPS and 20.0% appreciation over the current price of BDT 135. Table 9: DCF Valuation Discounted FCF (MM BDT) Operating Cash 1,039 1,435 2,000 2,464 2,770 2,913 Capital Expenditure Change in Debt ,366 2,009 2,506 2,850 3,017 Net Terminal Value 43,104 Terminal Value 49,432 Terminal Debt 6,328 FCFE 940 1,366 2,009 2,506 2,850 46,120 Discount Rate 13.0% Terminal Growth Rate 6.5% NPV (MM BDT) 34,002 NPV/Share 162 We also looked at the peer group of Beximco Pharma. The peers include the major listed pharmaceutical companies in Bangladesh. The peer group had an average P/E ratio of 29.5x and an average P/B ratio of 7.4x. Because of the recent dilution in Beximco s earnings the 45.4x P/E (trailing) may appear slightly richly valued. However, as we believe the company has high growth potential and the major value addition is going to occur post 2012, we considered the projected EPS and BVPS at the end of With a moderate earnings multiple of 18.0x and a conservative book value multiple of 2.0x, the comparative valuation gives us value per share of BDT 181 and BDT 183 respectively. We took the average of these two values and discounted them with a cost of equity of 14% to arrive at a fair value of BDT 160. Having considered both the DCF and relative valuation, we arrived at a fair value of BDT 160, giving us a 12- month total return of 19.8% including a dividend yield of 0.7%. We believe this is a good return considering the company had a large dilution recently. Table 10: Relative Valuation Other Pharmaceuticals Price EPS P/E BVPS P/B Square Pharmaceuticals x x Renata Limited x x ACI Limited x x GlaxoSmithKline x x Average 29.5x 7.4x Beximco Pharmaceuticals EPS BVPS 2012 Estimates Multiples 18.0x 2.0x Value/Share Average 182 Fair Value (Discounted at cost of equity) 160 Current Price 135 Dividend Yield 0.7% Total Return 19.8% Page 10
11 Table 11: Income Statement Income Statement (MM BDT) E 2011E 2012E Net Sales 3, , , , , ,632.4 Cost of Goods Sold 1, , , , , ,156.7 Gross Profit 1, , , , , ,475.7 Administrative Expenses Selling & Distribution Expenses , , , ,158.4 Operating Profit , , , ,934.5 Other Income Financial Cost Preference Share Dividend Profit Before WPPF , , ,076.7 Contribution to Workers' Profit Participation/Welfare Funds Profit Before Tax , , ,930.3 Tax Profit After Tax , , ,110.3 Diluted EPS (BDT) Source: Company Annual Reports and BRAC EPL Estimates Table 12: Cash Flow Statement Cash Flow Statement (MM BDT) E 2011E 2012E Net Profit After Tax 1, , ,110.3 Change in Working Capital Non-Cash Charges Other Changes Cash Flow from Operating Activities , , ,000.5 Capital Expenditure Other Investments 0.0 Cash Flow from Investing Activities , , Change in Debt Dividends Paid Cash flow from Financing Activities , Net Cash Flow , ,641.3 Opening Cash , , ,839.9 Closing Cash , , , ,481.3 Diluted CF Per Share (BDT) Source: Company Annual Reports and BRAC EPL Estimates Page 11
12 Table 13: Balance Sheet Balance Sheet (MM BDT) E 2011E 2012E Inventories 1, , , , , ,291.9 Spares & Supplies Accounts Receivable , ,516.0 Loans, Advances & Deposits , ,405.0 Short Term Investment 2, , , ,500.0 Cash & Cash Equivalent , , , ,481.3 Total Current Assets 2, , , , , ,680.5 Property, Plant & Equipment - Net 8, , , , , ,260.5 Intangible Assets Investment in Shares Total Non-Current Assets 9, , , , , ,269.1 Total Assets 11, , , , , ,949.6 Short Term Borrowings , , , , ,963.2 Long Term Borrowings - Current Maturity Creditors & Other Payables Accrued Expenses Dividend Payable Income Tax Payable Total Current Liabilities 1, , , , , ,454.5 Long Term Borrowings - Net of Current Maturity (Secured) 1, , , , , ,399.5 Fully Convertible, 5% Dividend, Preference Share 4,100.0 Liability for Gratuity & WPPF Deferred Tax Liability Total Non-Current Liabilities 2, , , , , ,298.8 Issued Share Capital 1, , , , , ,098.1 Share Premium 1, , , , , ,276.8 Excess of Issue Price over Face Value of GDRs 1, , , , , ,689.6 Capital Reserve on Merger Revaluation Surplus 1, , , , ,617.4 Retained Earnings 3, , , , , ,219.5 Total Shareholders' Equity 8, , , , , ,196.4 Total Liabilities and Shareholders' Equity 11, , , , , ,949.6 Diluted BVPS (BDT) Source: Company Annual Reports and BRAC EPL Estimates Page 12
13 Table 14: Indicators E 2011E 2012E Sales growth -2.84% 11.49% 21.40% 40.00% 30.00% 20.00% Earnings growth % 54.46% 14.56% % 39.01% 21.27% EBITDA (MM BDT) 1, , , , , ,162.0 EBITDA growth % 53.31% 0.98% 82.51% 31.34% 23.03% Dividend growth 10.00% % N/A N/A 50.00% 16.67% Dividend yield 0.00% 0.00% 0.00% 0.74% 1.11% 1.30% Cost of sales/sales 54.70% 49.94% 52.71% 49.00% 49.00% 48.50% Gross profit (MM BDT) 1, , , , , ,475.7 Gross profit margin 45.30% 50.06% 47.29% 51.00% 51.00% 51.50% Operating profit (MM BDT) , , , ,934.5 Operating margin 18.20% 24.91% 20.57% 26.70% 26.90% 27.60% Net profit (MM BDT) , , ,110.3 Net margin 9.82% 13.60% 12.83% 18.37% 19.64% 19.85% Return on equity 4.36% 5.83% 5.86% 9.30% 10.40% 11.52% Return on assets 2.96% 4.07% 3.60% 6.05% 7.73% 8.53% EBITDA margin 37.52% 51.59% 42.92% 55.95% 56.53% 57.95% Diluted Book value per share Diluted Earnings per share Diluted Cash Flow per share Debt/equity 36.69% 34.03% 33.85% 25.00% 25.00% 25.00% Debt/assets 25.33% 24.00% 18.53% 18.67% 18.54% 18.49% Equity growth rate 3.79% 26.65% 4.17% 47.24% 8.89% 9.99% P/E 80.3x 52.0x 45.4x 22.6x 16.3x 13.4x P/B 3.4x 2.7x 2.6x 1.8x 1.6x 1.5x EV (MM BDT) 31, , , , , ,662.7 EV/EBITDA 23.2x 15.4x 14.8x 8.0x 6.0x 4.7x Source: Company Annual Reports and BRAC EPL Estimates Page 13
14 IMPORTANT DISCLOSURES Analyst Certification: Each research analyst and research associate who authored this document and whose name appears herein certifies that the recommendations and opinions expressed in the research report accurately reflect their personal views about any and all of the securities or issuers discussed therein that are within the coverage universe. Disclaimer: Estimates and projections herein are our own and are based on assumptions that we believe to be reasonable. Information presented herein, while obtained from sources we believe to be reliable, is not guaranteed either as to accuracy or completeness. Neither the information nor any opinion expressed herein constitutes a solicitation of the purchase or sale of any security. As it acts for public companies from time to time, BRAC-EPL may have a relationship with the above mentioned company(s). This report is intended for distribution in only those jurisdictions in which BRAC-EPL is registered and any distribution outside those jurisdictions is strictly prohibited. Compensation of Analysts: The compensation of research analysts is intended to reflect the value of the services they provide to the clients of BRAC-EPL. As with most other employees, the compensation of research analysts is impacted by the overall profitability of the firm, which may include revenues from corporate finance activities of the firm's Corporate Finance department. However, Research analysts' compensation is not directly related to specific corporate finance transaction. General Risk Factors: BRAC-EPL will conduct a comprehensive risk assessment for each company under coverage at the time of initiating research coverage and also revisit this assessment when subsequent update reports are published or material company events occur. Following are some general risks that can impact future operational and financial performance: (1) Industry fundamentals with respect to customer demand or product / service pricing could change expected revenues and earnings; (2) Issues relating to major competitors or market shares or new product expectations could change investor attitudes; (3) Unforeseen developments with respect to the management, financial condition or accounting policies alter the prospective valuation; or (4) Interest rates, currency or major segments of the economy could alter investor confidence and investment prospects. BRAC EPL Stock Brokerage Capital Markets Group Aminul Haque Head of Capital Markets amin@bracepl.com Md. Monirul Islam Research Analyst monirul@bracepl.com Parvez Morshed Chowdhury Research Analyst parvez@bracepl.com Ali Imam Investment Analyst imam@bracepl.com Asif Khan Investment Analyst asif@bracepl.com Md. Ashfaque Alam Research Associate ashfaque@bracepl.com Khandakar Safwan Saad Research Associate safwan@bracepl.com BRAC EPL Research WW Tower (7 th Floor) 68 Motijheel C/A, Dhaka-1000 Tel: Fax: research@bracepl.com
Bata Shoe Bangladesh. Parvez M Chowdhury Analyst: Pharmaceuticals and Consumer Goods Rating: OUTPERFORM February 15, 2010
Price, BDT Turnover, MM Parvez M Chowdhury Analyst: Pharmaceuticals and Consumer Goods parvez@bracepl.com Bata Shoe Bangladesh DSE: Bloomberg: BATASHOE BATASH:BD Company Summary 52-week Price Range BDT
More informationTop Pharmaceutical Companies
Parvez M Chowdhury (880) 174 167 4023; parvez@bracepl.com Top Pharmaceutical Companies Sector Rating: Outperform March 1, 2010 Square Pharma 2009A 2010E 2011E Revenue (MM BDT) 11,826.2 13,025.7 15,098.9
More informationParvez M Chowdhury Analyst: Pharmaceuticals and Consumer Goods
Parvez M Chowdhury Analyst: Pharmaceuticals and Consumer Goods parvez@bracepl.com British American Tobacco Bangladesh DSE: BATBC; Bloomberg: BATBC:BD Rating: OUTPERFORM January 20, 2010 Company Summary
More informationRNS Number : 2501V Beximco Pharmaceuticals Ltd 27 January 2017
RNS Number : 2501V Beximco Pharmaceuticals Ltd 27 January 2017 BEXIMCO PHARMACEUTICALS LTD. 27 January, 2017 Half Year Results 2016-17 Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol:
More informationTitas Gas Transmission and Distribution Company Limited Fair Value Estimate (Dec 14) : BDT 111 per share Sector : Fuel and Power; Rating: OUTPERFORM
Dec-11 Jan-12 Feb-12 Mar-12 Apr-12 May-12 Jun-12 Jul-12 Sep-12 Sep-12 Nov-12 Dec-12 Jan-13 Jan-13 Feb-13 Apr-13 Apr-13 May-13 Jun-13 Jul-13 Sep-13 Oct-13 Nov-13 Dec-13 Jan-14 Feb-14 Price, BDT Turnover,
More informationIPO Note on Indo-Bangla Pharmaceuticals Limited
IPO Note on Indo-Bangla Pharmaceuticals Limited Key IPO Facts IPO Size (BDT mn) 200 IPO Size (Shares mn) 20 Public Offer Price Per Share (BDT) 10 Authorized Capital (BDT mn) 1,000 Pre-IPO Paid up Capital
More informationLafarge Surma Cement Ltd. March 4, 2010
Aminul Haque, CFA (880) 171 417 8460; amin@eplbangladesh.com Md. Ashfaque Alam (Research Associate) ashfaque@bracepl.com Lafarge Surma Cement Ltd. March 4, 2010 Rating: OUTPERFORM Target Price: BDT 575
More informationBDH Industries Limited BSE Scrip Code:
BDH Industries Limited BSE Scrip Code: 524828 Pharmaceuticals October 23, 2012 Equity Statistics Current Market Price Rs. 16.95 52 Week High/Low Rs. 21.00/13.15 Market Capitalisation Rs. Crores 9.76 Free
More informationOur core lies in quality, performance and courage
Our core lies in quality, performance and courage Tabuk Pharmaceuticals develops, manufactures, markets and distributes branded generic pharmaceuticals and under-licensed products globally, with a strong
More informationDhaka Electric Supply Company (DESCO)
Thousands Aminul Haque, CFA (880) 171 417 8460; amin@eplbangladesh.com Dhaka Electric Supply Company (DESCO) November 2009 Recommendation: BUY Target Price: BDT 1,700 Company Summary 52-week Price Range
More informationACME Laboratories Limited
City Bank Capital - IPO Notes ACME Laboratories Limited ACME Laboratories Limited Cut-off Price IPO Book Building: BDT 85.2 and Offer Price IPO Subscription: BDT 77.0 per share [with BDT 75.2 and BDT 66.0
More informationWe believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Independent Auditors Report To The Shareholders of BEXIMCO PHARMACEUTICALS LIMITED Report on the Financial Statements We have audited the accompanying financial statements of Beximco Pharmaceuticals Limited,
More informationAuditors Report To The Shareholders of BEXIMCO PHARMACEUTICALS LIMITED
Auditors Report To The Shareholders of BEXIMCO PHARMACEUTICALS LIMITED Introduction We have audited the accompanying financial statements of Beximco Pharmaceuticals Limited, which comprise of the Statement
More informationAurobindo Pharma Limited Presentation to Investors
Aurobindo Pharma Limited Presentation to Investors February 2013 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation,
More informationJ.B. Chemicals & Pharmaceuticals Ltd.
Oct-16 Nov-16 Nov-16 Dec-16 Jan-17 Jan-17 Feb-17 Mar-17 Apr-17 Apr-17 May-17 Jun-17 Jun-17 Jul-17 Aug-17 Aug-17 Sep-17 Oct-17. Volume No.. I Issue No. 146 J.B. Chemicals & Pharmaceuticals Ltd. October
More informationINDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE FIRST QUARTER FY16. Apr Mar. 15 Net Sales : Jan. 15 Mar. 15
INDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE FIRST QUARTER FY16 Financials (` In Lacs) Unaudited Audited Particulars Quarter Ended Year Ended Apr. 15 Jun. 15 Jan. 15 Mar. 15 Apr. 14
More informationJUBILANT LIFE SCIENCES Q4/FY2017 RESULTS
PRESS RELEASE Noida, Tuesday, May 23, 2017 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q4/FY2017 RESULTS JUBILANT REPORTS
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global Healthcare Conference June 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect to our
More informationLincoln Pharmaceuticals Limited
25 January 2016 CMP: Rs.219.5 Industry: Healthcare BSE Group/Index: B/ Promoters Patel family Year of incorporation 1995 Registered office Lincoln House, B/h Satyam Complex, Science City Road, Viilage
More informationLupin Investor Presentation Q3FY14
Lupin Investor Presentation Q3FY14 Vision: To be an innovation led transnational company Safe harbor statement Materials and information provided during this presentation may contain forward looking statements.
More informationCambrex to Acquire Halo Pharma. July 23, 2018
Cambrex to Acquire Halo Pharma July 23, 2018 Forward-Looking Statements Statements in this presentation regarding the acquisition of Halo Pharma ( Halo ) and expected benefits therefrom (including revenue
More informationAuditors Report To The Shareholders of BEXIMCO PHARMACEUTICALS LIMITED
Auditors Report To The Shareholders of BEXIMCO PHARMACEUTICALS LIMITED We have audited the accompanying Balance Sheet of the Beximco Pharmaceuticals Limited as of December 31, 2009 and the related Profit
More informationINDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE SECOND QUARTER FY15. Revenue figures
INDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE SECOND QUARTER FY15 Revenue figures (` In Lacs) Unaudited Audited Particulars July 14 Sept. 14 Quarter Ended Apr. 14 Jun. 14 July 13 Sept.
More informationJenburkt Pharmaceuticals Limited
Jenburkt Pharmaceuticals Limited Date: 3 rd February, 2016 Stock Performance Details Shareholding Details October 2015 Current Price : ` 418.0^ Face Value : ` 10 per share 52 wk High / Low : ` 542.8 /
More informationAurobindo Pharma Limited. Presentation to Investors
Aurobindo Pharma Limited Presentation to Investors November 2013 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation,
More informationALEMBIC PHARMACEUTICALS LTD.(APL)
ALEMBIC PHARMACEUTICALS LTD.(APL) Date : 13 th September, 212 Stock Performance Details Current Price : Rs. 73.35** Face Value : Rs. 2 per share 52 wk High / Low : Rs. 78.95 / Rs.34. Total Traded Volumes
More information3QFY09 revenues in line but adjusted margins beat KIE. No changes in estimates for FY E
India Daily Summary - January 29, 2009 LUPIN January 29, 2009 Pharmaceuticals LUPN.BO, Rs562 Rating Sector coverage view Target Price (Rs) BUY Attractive 950 52W High -Low (Rs) 782-438 Market Cap (Rs bn)
More informationFIDSON HEALTHCARE PLC.
FIDSON HEALTHCARE PLC. EQUITY NIGERIA HEALTHCARE GTI Securities Research Coverage Analyst: Morolake Bisi-Afolabi Lead Analyst: Chuks Anyanwu c.anyanwu@gti.com.ng DECEMBER 15 th, 2015 Recommendation: BUY
More informationInstitutional Presentation. June/2016
V2 Institutional Presentation June/2016 Disclaimer This release contains forward-looking statements that are exclusively related to the prospects of the business, its operating and financial results, and
More informationIPCA Laboratories Ltd 26 th August, 2013 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY IPCA Laboratories Ltd 26 th August, 2013 BUY CMP(As on 24/8/13) Rs.623.30 Target Price Rs.780.00 BSE Code 524494 NSE Code IPCALAB Market
More informationCurrent trends in generic medicines in the Middle East: challenges and opportunities. Mazen Darwazah Vice Chairman, Hikma Pharmaceuticals PLC
Current trends in generic medicines in the Middle East: challenges and opportunities Mazen Darwazah Vice Chairman, Hikma Pharmaceuticals PLC Middle East and North African pharmaceutical markets Middle
More informationBRAC Bank Ltd DSE: BRACBANK Bloomberg: BRAC:BD
Price, BDT Turnover, BDT MM Analysts: Sajid Huq sajid.huq@bracepl.com Farjad Siddiqui farjad.siddiqui@bracepl.com DSE: BRACBANK Bloomberg: BRAC:BD Company Summary Ticker BRACBANK Sector Bank Date of Operation
More information23 rd December Initiating Coverage. Q4 FY17 Earnings Update
23 rd December 2017 Initiating Coverage Q4 FY17 Earnings Update Disclaimer The information contained herein is obtained from sources believed to be reliable. Guiness Securities Ltd is not responsible or
More informationBaltic Nordic Roadshow presentation. October, 2015
Baltic Nordic Roadshow presentation October, 2015 In This Presentation Olainfarm the background and the key facts; The Group Company s recent performance; Ukraine and Russia: present and prospects; Future
More informationInvestor Presentation
Investor Presentation www.ajantapharma.com 1 BSE Symbol : AJANTAPH Code: 532331 NSE Symbol : AJANTPHARM ISIN: INE031B01031 Safe Harbour Statement This presentation may include certain forward looking statements,
More informationNATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16
ISIN: INE987B01018 OCTOBER 15 th, 2015 STOCK DETAILS Sector NATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16 BSE Code 524816 Face Value 10.00 Pharmaceuticals 52wk. High / Low (Rs.) 2709.00/1245.40
More informationInterim Financial Statements (Un-audited) 1 st Quarter Ended September 30, 2016
Interim Financial Statements (Un-audited) 1 st Quarter Ended September 30, 2016 Beximco Pharmaceuticals Limited 1 Statement of Financial Position (Un-audited) September 30, 2016 Notes September 30, 2016
More informationJUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS
PRESS RELEASE Noida, Tuesday, May 24, 2016 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS JUBILANT
More informationInterim Financial Statements (Un-audited) For the Half Year Ended December 31, 2017
Interim Financial Statements (Un-audited) For the Half Year Ended December 31, 2017 Beximco Pharmaceuticals Limited Statement of Financial Position (Un-audited) December 31, 2017 Notes December 31, 2017
More informationInterim Report First Six Months 2000
Interim Report First Six Months 2000 Sales Development (millions of lire) 1st quarter 150,000 Highlights First Six Months 2000 127,273 147,789 140,000 130,000 120,000 110,000 100,000 0 2nd quarter 155,456
More informationLupin Ltd. Investor Presentation Q2 FY Oct 28, 2014
Lupin Ltd. Investor Presentation Q2 FY2014-15 Oct 28, 2014 Safe harbor statement Materials and information provided during this presentation may contain forward-looking statements. These statements are
More informationAn Overview of World Goods and Services Trade
Appendix IV An Overview of World Goods and Services Trade An overview of the size and composition of U.S. and world trade is useful to provide perspective for the large U.S. trade and current account deficits
More informationAceto Corporation. NASDAQ: ACET Investor Update November 2018
Aceto Corporation NASDAQ: ACET Investor Update November 2018 Disclosure This presentation contains forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, that can
More informationChina TCM (570 HK) Buy (maintained) Target price: HK$ H17 earnings beat, 2017 growth guidance reaffirmed; TP raised to HK$5.
Oct-14 Dec-14 Feb-15 Apr-15 Jun-15 Aug-15 Oct-15 Dec-15 Feb-16 Apr-16 Jun-16 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Equity Research Healthcare China TCM (570 HK) Buy (maintained) Target price: HK$5.40
More informationACETO Corporation. June 8, 2016
NASDAQ:ACET ACETO Corporation Jefferies Healthcare Conference June 8, 2016 Sourcing & Supplying Quality Products Worldwide Disclosure This presentation contains forward-looking statements, as defined by
More informationInterim Financial Statements (Un-audited) 1 st Quarter Ended September 30, 2017
Interim Financial Statements (Un-audited) 1 st Quarter Ended September 30, 2017 Beximco Pharmaceuticals Limited Statement of Financial Position (Un-audited) September 30, 2017 ASSETS Notes September 30,
More informationACETO Corporation NASDAQ: ACET. Investor Presentation February 2018
ACETO Corporation NASDAQ: ACET Investor Presentation February 218 Disclosure This presentation contains forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, that
More informationDong-A Pharmaceutical ( KS)
Dong-A Pharmaceutical (64 KS) Trading Buy (Initiate) Target Price (12M, W) 115, Share Price (9/3/12, W) 94,6 Expected Return (%) 21.6 EPS Growth (12F, %) -3.7 Market EPS Growth (12F, %) 12.7 P/E (12F,
More informationHIKMA PHARMACEUTICALS PLC UBS GLOBAL GENERIC & SPECIALITY PHARMACEUTICALS CONFERENCE NEW YORK 8-9 MAY 2007
HIKMA PHARMACEUTICALS PLC UBS GLOBAL GENERIC & SPECIALITY PHARMACEUTICALS CONFERENCE NEW YORK 8-9 MAY 2007 About Hikma Founded in Jordan in 1978 Multinational business developing, manufacturing and marketing
More informationACETO Corporation NASDAQ: ACET. Update May 2018
ACETO Corporation NASDAQ: ACET Update May 218 Disclosure This presentation contains forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, that can be identified
More informationOverview. Highlights. Financial highlights
Injectables Our Injectables business manufactures, markets and sells generic injectable products in the US, the MENA region and Europe. In the US, we are the third largest manufacturer of injectables by
More informationROADSHOW POST-Q2 & H RESULTS. September 2016
ROADSHOW POST-Q2 & H1 2016 RESULTS September 2016 1. COMPANY OVERVIEW Rexel at a glance : Strategic partner for suppliers and customers Energy Providers Suppliers Customers Endusers Economies of scale
More informationCadila Healthcare Ltd.
Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 s. Cadila Healthcare Ltd.. August 8, 216 BSE Code: 532321 NSE Code: CADILAHC Reuters Code: CADI.NS Bloomberg Code:
More informationCompany Overview. Financial Performance
Jan/15 Feb/15 Mar/ Apr/15 May/ Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/ Dec/15 Parnax Lab Limited CMP: 53.90 January 08, 2016 Stock Details BSE code 506128 BSE ID PARNAXLAB Face value ( ) 10 No of shares
More informationDIL Ltd. Pharmaceuticals. Company Overview. Company Fundamentals. CMP Rs
Pharmaceuticals September 26, 2012 CMP Rs. 700.4 BSE Code 506414 BSE ID DIL High/Low 1Y (Rs.) 748.2 / 373.9 Average Volume (3M) 579.8 Market Cap (Rs. Cr.) 161.1 Shareholding % Jun-12 Mar-12 Promoters 63.20
More informationDr Reddy s Laboratories Ltd. Q4 FY07 and FY07 Financial Performance Review
Dr Reddy s Laboratories Ltd. NYSE:RDY Q4 and Financial Performance Review Table of Contents USGAAP Financial Snapshot 02 Revenue Mix 03 Active Pharmaceutical Ingredients 04 Generic Formulations 05 Branded
More informationGlaxoSmithKline Pharmaceuticals Limited Annual Analyst Meet, September 2017
GlaxoSmithKline Pharmaceuticals Limited Annual Analyst Meet, 2017 1 September 2017 GlaxoSmithKline Pharmaceuticals Limited Analyst Update 1 September 2017 A. Vaidheesh, Managing Director Andrew Aristidou,
More informationStrides Arcolab. CMP: INR717 TP: INR829 Buy
BSE SENSEX S&P CNX 17,144 5,200 Bloomberg STR IN Equity Shares (m) 57.7 52-Week Range (INR) 794/276 1,6,12 Rel. Perf. (%) -2/37/98 M.Cap. (INR b) 41.4 M.Cap. (USD b) 0.7 31 July 2012 2QCY12 Results Update
More informationSaakh Pharma (Private) Limited
RATING REPORT Saakh Pharma (Private) Limited REPORT DATE: October 25, 2018 RATING ANALYSTS: Talha Iqbal talha.iqbal@jcrvis.com.pk Muhammad Tabish Muhammad.tabish@jcrvis.com.pk RATING DETAILS Initial Rating
More informationInterim Financial Statements (Un-audited) For the Half Year Ended December 31, 2016
Interim Financial Statements (Un-audited) For the Half Year Ended December 31, 2016 Beximco Pharmaceuticals Limited Statement of Financial Position (Un-audited) As at December 31, 2016 ASSETS Notes As
More informationLUPIN LIMITED. Q3 FY18 Investor Presentation. February 06, 2018
LUPIN LIMITED Q3 FY18 Investor Presentation February 06, 2018 Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global London Healthcare Conference November 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect
More informationSopharma (3JR) 11 January Company overview
Company overview The pharmaceutical company Sopharma (3JR) is the second largest producer of medicines in Bulgaria. The group is vertically integrated and the holding company Sopharma is the majority owner
More informationSaudi Ceramic Expansion plan key growth driver
RSI10 Construction and Materials Industrial SCERCO AB: Saudi Arabia Rating NEUTRAL Target price SAR116. 0 (4.5% upside) Current SAR111.3 price Key themes & implications Company is one of the leading ceramic
More informationConsumer goods continue to drive Bangladesh Economy Sector Report May 8, 2011
M M Shahnewaz Kabir Shawon Research Associate shahnewaz@bracepl.com Consumer goods continue to drive Bangladesh Economy Sector Report May 8, 2011 Bangladesh is home to the eighth largest population in
More informationCompany Update: Fidson Healthcare Plc
27 July 2017 In this report, we provide an update on Fidson Healthcare Plc following the opening of its World Health Organisation (WHO) certified manufacturing plant last year and the organic expansion
More informationGranules India Ltd. 21 st July, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Granules India Ltd. 21 st July, 2012 CMP Target Price Rs.149.30 Rs.200.00 Granules India is among the leading global manufacturer of highvolume
More informationH Results. Christian Buhl, CEO Roland Iff, CFO August 14, 2018
H1 2018 Results Christian Buhl, CEO Roland Iff, CFO August 14, 2018 Agenda H1 2018 at a glance Building industry outlook 2018 Outlook 2018 SLIDE 2 Successful first half of 2018 with strong earnings growth
More informationChina Pharma Holdings, Inc. Reports Full Year 2016 Financial Results
China Pharma Holdings, Inc. Reports Full Year 2016 Financial Results HAIKOU CITY, China, March 31, 2017 - China Pharma Holdings, Inc. (NYSE MKT: CPHI) ( China Pharma, the Company or We ), an NYSE MKT listed
More informationREIG JOFRE INCREASES SALES BY 7%, EBITDA BY 12,5% AND NET PROFIT BY 7,5% AT THE END OF JUNE
Barcelona (Spain), July 26, 2018 RESULTS NOTE: FIRST HALF 2018 REIG JOFRE INCREASES SALES BY 7%, EBITDA BY 12,5% AND NET PROFIT BY 7,5% AT THE END OF JUNE The company reached 90.1 M in sales (+ 7%), driven
More informationPharmaceuticals Industry of Bangladesh
Pharmaceuticals Industry of Bangladesh (This document has been prepared by the Research team of EBLSL Securities Limited) for information only of its clients. No part of this report should be copied or
More informationExecutive Summary. The Transatlantic Economy Annual Survey of Jobs, Trade and Investment between the United States and Europe
The Transatlantic Economy 2011 Annual Survey of Jobs, Trade and Investment between the United States and Europe Daniel S. Hamilton Daniel S. Hamilton and Joseph P. Quinlan and Joseph P. Quinlan Center
More informationQ4 FY17-18 EARNINGS PRESENTATION
Q4 FY17-18 EARNINGS PRESENTATION 28 th May 2018 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to the
More informationSecond quarter Vestas Wind Systems A/S. Copenhagen, 18 August Classification: Public
Second quarter Vestas Wind Systems A/S Copenhagen, 18 August Disclaimer and cautionary statement This presentation contains forward-looking statements concerning Vestas' financial condition, results of
More informationCatalent, Inc. Raymond James Institutional Investors Conference. March 7, 2016
Catalent, Inc. Raymond James Institutional Investors Conference March 7, 2016 Disclaimer Statement Forward-Looking Statements This press release contains both historical and forward-looking statements.
More informationAspen increases revenue by 16% to R41.2 billion
Aspen Pharmacare Holdings Limited ( Aspen ) (Incorporated in the Republic of South Africa) (Registration Number 1985/002935/06) (Share code APN ISIN: ZAE000066692) PRESS RELEASE Embargo: 14 September 2017
More informationPFIZER LIMITED Result Update (PARENT BASIS): Q1 FY15
PFIZER LIMITED Result Update (PARENT BASIS): Q1 FY15 ISIN: INE182A01018 SEPTEMBER 29 th,2014 Recommendation BUY CMP 1634.05 Target Price 1797.00 STOCK DETAILS Sector BSE Code 500680 Face Value 10.00 Pharmaceuticals
More informationSQS India BFSI Ltd HOLD. Impact of Macro Headwinds Still Hurting; Revenue from US May Pick up in FY18E
Company Update Impact of Macro Headwinds Still Hurting; Revenue from US May Pick up in FY18E EBITDA Margins recovered by 618 bps QoQ: The company has witnessed many challenges over the year FY17 starting
More informationSource: Company Data; PL Research
US generics, low RM costs lead to margin surprise May 08, 2014 Surajit Pal surajitpal@plindia.com +91 22 66322259 Rating Accumulate Price Rs990 Target Price Rs1,156 Implied Upside 16.8% Sensex 22,324 Nifty
More informationJUBILANT LIFE SCIENCES Q2 & H1 FY19 RESULTS
PRESS RELEASE Noida, Monday, Oct 22, 2018 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q2 & H1 FY19 RESULTS JUBILANT
More informationChief Executive Officer
Said Darwazah Chief Executive Officer 211 highlights Strong Group performance in a challenging year 95 9 MSI PROMOPHARM $11.2 m $918.m 85 8 75 BRANDED + 9.6% $37.9 m INJECTABLES + 23.3% $36.7 m GENERICS
More informationHardick Bora 4QCY12 Results Update Sector: Healthcare Sanofi India CMP: INR2,307 TP: INR2,015 Neutral
BSE Sensex S&P CNX 19,332 5,855 Bloomberg SANL IN Equity Shares (m) 23.0 M.Cap. (INR b)/(usd b) 53.1/1.0 52-Week Range (INR) 2,450/2,002 1,6,12 Rel. Perf. (%) 9/-1/-4 Financials & Valuation (INR b) Y/E
More information9M 2018 Results. Christian Buhl, CEO Roland Iff, CFO October 30, 2018
9M 2018 Results Christian Buhl, CEO Roland Iff, CFO October 30, 2018 Agenda Q3 2018 key figures 9 months 2018 results Building industry outlook Outlook SLIDE 2 Q3 2018 results Sales growth (reported) Sales
More informationI N T E R I M R E P O R T 2nd Quarter 2001 M
I N T E R I M R E P O R T M 2 nd quarter 2001 2 Organic growth, driven by the pharmaceuticals and laboratory distribution divisions, resulted in: Sales + 16 % to EUR 1,949 million. 2 Indicators of earnings
More informationAssessing the impact of proposals for a Supplementary Protection Certificate (SPC) Manufacturing Exemption in the EU
White paper Assessing the impact of proposals for a Supplementary Protection Certificate (SPC) Manufacturing Exemption in the EU Ramya Logendra, Engagement Manager, Supplier and Association Relations Per
More informationQ2 FY18-19 EARNINGS PRESENTATION
Q2 FY18-19 EARNINGS PRESENTATION 12 th November 2018 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to
More informationAlembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd Investor Presentation May-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Annual Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual 7.
More information2Q 19 Earnings Call Presentation. February 5, 2019
2Q 19 Earnings Call Presentation February 5, 2019 Agenda John Chiminski, Chair & Chief Executive Officer 2Q 19 Highlights Wetteny Joseph, Senior VP & Chief Financial Officer Business Update by Segment
More informationDISHMAN CARBOGEN AMCIS LIMITED. Q3 & 9M FY18 RESULTS UPDATE January 2018
DISHMAN CARBOGEN AMCIS LIMITED Q3 & 9M FY18 RESULTS UPDATE January 2018 1 SAFE HARBOR STATEMENT This presentation and the following discussion may contain forward looking statements by Dishman Carbogen
More informationAlembic Pharmaceuticals Ltd
Pharmaceuticals Ltd Investor Presentation January-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Nine Months Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual Safe
More informationForeign Direct Investment in the United States 2013 Preliminary Data. Organization for International Investment (OFII)
Foreign Direct Investment in the United States 2013 Preliminary Data Organization for International Investment (OFII) Key Findings: Foreign Direct Investment in the United States, 2003-2013 1 Foreign direct
More informationCadila Healthcare ACCUMULATE. Performance Highlights. CMP 860 Target Price QFY2013 Result Update Pharmaceutical. Key financials (Consolidated)
2QFY2013 Result Update Pharmaceutical November 7, 2012 Cadila Healthcare Performance Highlights ACCUMULATE CMP 860 Target Price 926 Y/E March (` cr) 2QFY2013 1QFY2013 % chg (qoq) 2QFY2012 % chg (yoy) Investment
More informationStrong Margins, Robust Profitability Quarter I Results, FY EBITDA up 44%, Net profit up 43%
Strong Margins, Robust Profitability Quarter I Results, FY 2013 14 EBITDA up 44%, Net profit up 43% Mumbai, Aug 7, 2013: Pharma Major, Lupin Ltd. reported its performance for the first quarter ending 30
More informationFLASH NOTE EQUITY RESEARCH. OUTPERFORM Price target 6.40 Price Elanix Biotechnologies AG (ELN-DE) Updates from webcast include financial outlook
ELANIX BIOTECHNOLOGIES AG Biotechnology 8 August 2018 09:54 BST FLASH NOTE Elanix Biotechnologies AG (ELN-DE) Updates from webcast include financial outlook OUTPERFORM Price target 6.40 Price 2.72 KEY
More informationAllianz Global Corporate & Specialty
Allianz Global Corporate & Specialty Company presentation January 2012 Allianz An Introduction Allianz Group is one of the world s leading insurers and financial services providers Founded in 1890 in Berlin,
More informationThe contents of this document must be taken into account by all individuals or entities that may have to make decisions or draw up or
Corporate Presentation September 2018 Disclaimer This document has been prepared by NATURHOUSE HEALTH S.A. ( NATURHOUSE or the Company ) for its exclusive use during the presentations to investors. NATURHOUSE
More informationKION UPDATE CALL Q Gordon Riske, CEO Thomas Toepfer, CFO Wiesbaden, 7 May 2015
KION UPDATE CALL 2015 Gordon Riske, CEO Thomas Toepfer, CFO Wiesbaden, 7 May 2015 AGENDA 1 Highlights Gordon Riske 2 Market update Gordon Riske 3 Financial update Thomas Toepfer 4 Outlook Gordon Riske
More informationQ3 FY17-18 EARNINGS PRESENTATION. 7 th February 2018
Q3 FY17-18 EARNINGS PRESENTATION 7 th February 2018 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to
More informationMarket Release November
Market Release November 23 2017 FINANCIAL RESULTS FOR HALF YEAR ENDED 30 SEPTEMBER 2017 AFT Pharmaceuticals Limited (NZX; AFT, ASX; AFP) today announced its half-year unaudited financial results for the
More informationQ Earnings Call
We make healthy possible Q3 2018 Earnings Call Financial Results and Business Update November 7, 2018 Safe Harbor Statement & Non-GAAP Financial Measures Safe Harbor Statement Certain statements contained
More information